Research programme: infectious disease therapeutics - Auritec/pSivida

Drug Profile

Research programme: infectious disease therapeutics - Auritec/pSivida

Latest Information Update: 10 Oct 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator pSivida
  • Developer Auritec Pharmaceuticals
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 10 Oct 2012 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 10 Oct 2012 Discontinued - Preclinical for Viral infections in USA (unspecified route)
  • 11 Jan 2007 Preclinical trials in Bacterial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top